aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Cloudbreak Therapeutics, founded with a mission to innovate ocular drug development, is a clinical-stage biotechnology company. The company repurposes approved systemic drugs for ocular delivery to treat various eye diseases. Utilizing a capital-efficient business model based on VIC and 505(b)(2) pathways, Cloudbreak aims to quickly advance drug candidates through Phase II clinical trials and out-license global rights for further development and commercialization. Their product pipeline includes treatments for conditions such as pterygium, myopia progression, MGD, pinguecula, and diabetic macular edema.
Notable figures affiliated with Cloudbreak Therapeutics include an experienced management team and a distinguished scientific advisory board. The company has achieved significant milestones, including advancing multiple drug candidates to proof-of-concept Phase II clinical trials. Cloudbreak's innovative approach has positioned it as a promising player in the biotechnology sector, potentially transforming the treatment landscape for ocular diseases and improving patient outcomes globally.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Drug Development
Technology
Biotech
Tags
Biotech, Healthtech
Model Types
Licensing, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Cloudbreak Therapeutics founded?
Cloudbreak Therapeutics was founded in 2015.
Where is Cloudbreak Therapeutics’s headquarters located?
Cloudbreak Therapeutics’s headquarters is located in Irvine, CA, US.
When was Cloudbreak Therapeutics’s last funding round?
Cloudbreak Therapeutics’s most recent funding round was for $130M (USD) in January 2022.
How many employees does Cloudbreak Therapeutics have?
Cloudbreak Therapeutics has 30 employees as of Feb 4, 2024.
How much has Cloudbreak Therapeutics raised to-date?
As of July 05, 2023, Cloudbreak Therapeutics has raised a total of $171.2M (USD) since Jan 1, 2022.
Add Comparison
Total Raised to Date
$171.2M
USD
Last Update Jan 1, 2022
Last Deal Details
$130M
USD
Jan 1, 2022
Series C
Total Employees Over Time
30
As of Feb 2024
Cloudbreak Therapeutics Address
15615 Alton Pkwy
suite 450
Irvine,
California
92618
United States of America
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts